Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood molecule predict blood vessel damage in kids with kidney disease?

NCT ID NCT06300788

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study looks at whether levels of a molecule called inorganic pyrophosphate (PPi) in the blood are linked to blood vessel damage in children with chronic kidney disease (CKD). Researchers will compare PPi levels in children with CKD (including those on dialysis or with a kidney transplant) to levels in healthy children. The goal is to better understand why blood vessels harden in CKD and possibly find new ways to prevent it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study clarifies how pyrophosphate relates to blood vessel damage in children with kidney disease, it could point toward new ways to prevent or slow that damage.
What could go wrong
This is an observational study with a small number of participants (60 children). It measures molecules in the blood, so it cannot prove cause and effect or directly lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All groups : * Minor patients (\<18 years) * Patients of both sexes * Informed patients and parents who have signed the informed consent form * Patients affiliated to social security Control group : \- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up CKD groups : * Patients on dialysis for more than 3 months, regardless of technique * Kidney transplant patients * Patients with CKD, whatever the cause Exclusion Criteria: * Progressive cancer or kidney disease * Treatments that may modify PPi concentration (e.g. bisphosphonates)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pyrophosphate, fetuin A, IL1, IL6, tnfalpha, control

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Nice - Hôpital de l'Archet 2

    RECRUITING

    Nice, Alpes-Maritimes, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.